LEARN MORE FROM THE CLINICAL INVESTIGATORS

Select a presentation below to hear more about MAVYRET from clinical investigators, and discover why it may be appropriate to consider MAVYRET for your patients with chronic HCV infection.

<br/>

MAVYRET FOR 8 WEEKS IN TREATMENT-NAÏVE, CHRONIC HCV PATIENTS WITHOUT CIRRHOSIS

Playing video 1 of 4

video-poster-1

MAVYRET FOR 8 WEEKS IN TREATMENT-NAÏVE, CHRONIC HCV PATIENTS WITHOUT CIRRHOSIS

with Dr. Mitchell Shiffman and Dr. Fred Poordad

video-poster-2

MAVYRET FOR 12 WEEKS IN TREATMENT-NAÏVE, CHRONIC HCV PATIENTS WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A)

with Dr. Marcelo Kugelmas and Dr. Paul Pockros

video-poster-3

MAVYRET FOR CHRONIC HCV PATIENTS WITH SEVERE RENAL IMPAIRMENT

with Dr. Steve Flamm and Dr. Robert S. Brown

video-poster-4

MAVYRET FOR 16 WEEKS IN CHRONIC HCV GT1 PATIENTS WHO ARE NS5A INHIBITOR-EXPERIENCED AND NS3/4A PROTEASE INHIBITOR-NAÏVE

with Dr. Robert S. Brown and Dr. Steve Flamm

<br/>